The global clinical laboratory tests market size was valued at USD 145.66 billion in 2025 and is projected to grow from USD 155.11 billion in 2026 to USD 256.52 billion by 2034, registering a CAGR of 6.49% during the forecast period from 2026 to 2034. North America dominated the clinical laboratory tests market with a market share of 42.5% in 2025.
Clinical laboratory tests are diagnostic examinations performed on samples such as blood, urine, tissue, and other bodily fluids to detect, diagnose, monitor, or prevent diseases and health conditions. These tests can assess biomarkers, organ function, infections, genetic characteristics, and other health indicators. Clinical laboratory testing plays an important role in healthcare by providing accurate information that helps physicians make informed decisions about patient treatment and disease management.
Download a Free Sample To learn more about this report,
Growing Adoption of Blood-Based Biomarker Tests for Neurological Diseases
The clinical laboratory tests market is expanding into neurological diagnostics as blood-based biomarkers provide less invasive alternatives to procedures such as cerebrospinal-fluid testing and specialized imaging. Advances in protein assays are allowing laboratories to identify disease-associated biological changes from routine blood samples, making sophisticated neurological assessment easier to integrate into established laboratory workflows. This shift is broadening clinical testing beyond traditional chemistry and hematology. Blood-based neurological biomarkers are therefore becoming an important part of clinical laboratory tests market trends.
In August 2026, Roche received FDA clearance for its Elecsys pTau217 blood test for assessing amyloid pathology associated with Alzheimer's disease in patients aged 55 years and older. The assay can be deployed across an installed base of more than 4,500 compatible cobas laboratory instruments.
Increasing Automation of High-Volume Routine Laboratory Testing
Clinical laboratories are increasingly adopting end-to-end automation to handle growing sample volumes while reducing repetitive manual activities. Automated systems can integrate sample processing, analytical testing, imaging, and standardized result generation, allowing laboratory personnel to focus on exceptions and complex cases. This is particularly valuable for routine tests where large numbers of specimens must be processed consistently every day. Automation is consequently expanding the clinical laboratory tests industry toward higher-throughput diagnostic workflows.
In July 2026, Beckman Coulter Diagnostics launched the DxU 1800 fully automated urinalysis system, combining urine chemistry with microscopy in a single workflow. The system is designed to process up to 240 chemistry samples per hour, supporting laboratories facing rising routine-testing volumes.
Growing Need for Rapid Testing of Emerging Infectious Diseases
Emerging pathogens create immediate demand for laboratory tests that can distinguish new infections from diseases producing similar symptoms. Clinical laboratories play an important surveillance and diagnostic role because scalable molecular testing allows healthcare providers to identify infections beyond the capacity of specialized public-health laboratories alone. Rapid development of assays following new disease threats therefore creates recurring demand for molecular diagnostic services. Increasing infectious-disease preparedness is strengthening clinical laboratory tests market demand.
In July 2025, Quest Diagnostics launched a diagnostic laboratory test for Oropouche virus using molecular testing to detect viral RNA. The test was introduced as infections expanded geographically and was designed to provide scalable clinical testing alongside public-health laboratory capacity.
Regulatory Uncertainty Surrounding Laboratory-Developed Tests
Laboratory-developed tests are important for specialized diagnostics, but changing regulatory interpretations can make investment and commercialization decisions difficult for laboratories. Organizations need clarity about whether new tests will require additional registration, quality-system controls, labeling, or premarket review before committing resources to assay development. Regulatory reversals can also force laboratories to reassess compliance strategies already under preparation. Such uncertainty can restrain clinical laboratory tests market growth by complicating long-term planning for specialized testing.
In September 2025, the U.S. Food and Drug Administration formally reverted its laboratory-developed-test regulation after a federal court vacated the previous final rule on March 31, 2025. The change reversed a planned framework that had included 5 stages of progressively expanded regulatory requirements.
Expansion of Blood Testing for Mild Traumatic Brain Injury
Concussion assessment creates a distinct opportunity because many patients with suspected mild traumatic brain injury undergo CT imaging primarily to exclude more serious intracranial injury. Laboratory biomarkers can provide objective information from blood samples and help clinicians determine which patients are less likely to require imaging. Faster laboratory assessment could reduce unnecessary radiation exposure and emergency-department resource use. Traumatic-brain-injury diagnostics can therefore help suppliers increase clinical laboratory tests market share through new acute-care applications.
In June 2025, Abbott launched its laboratory-based mild traumatic brain injury blood test, which provides results in approximately 18 minutes when run on compatible laboratory analyzers. The test can potentially eliminate the need for CT imaging in up to 40% of evaluated patients.
Differentiating Bacterial From Viral Infections Quickly Enough to Guide Treatment
Patients with bacterial and viral infections can present with similar symptoms, making rapid differentiation difficult using clinical assessment alone. Delayed or uncertain results can lead to unnecessary antibiotic treatment, additional diagnostic procedures, or avoidable hospital admissions. Clinical laboratories therefore need assays that provide actionable information within the treatment window while maintaining adequate diagnostic accuracy. Delivering this combination of speed and clinical discrimination remains a major challenge as clinical laboratory tests market size expands.
In April 2026, Beckman Coulter Diagnostics received CE marking for the Access MeMed BV assay, which differentiates bacterial from viral infections in approximately 20 minutes. Health-economic modeling associated with the test estimated that its adoption could avoid up to EUR 80 million in unnecessary healthcare costs.
Clinical Chemistry Tests - Basic Metabolic Panel (BMP) Segment Dominated the Market with 15.2% Share in 2025
The clinical chemistry tests—basic metabolic panel (BMP) segment dominated the global clinical laboratory tests market with a 15.2% market share in 2025, valued at USD 22.14 billion. The segment's leadership is supported by the routine use of BMP testing to assess glucose levels, electrolyte balance, kidney function, and metabolic health. Its widespread use in preventive examinations, disease monitoring, emergency care, and routine clinical decision-making contributes to consistent testing volumes across healthcare facilities.
Other test categories, including hematology, microbiology, immunology, molecular diagnostics, and urinalysis, continue to play important roles in disease detection and patient monitoring. Advances in laboratory automation, molecular testing, and genomic technologies are expanding diagnostic capabilities and enabling laboratories to deliver more precise and clinically useful results.
Request Customizationto receive a tailored report.
Diagnostic Laboratories Segment is Projected to Register the Fastest Growth at a CAGR of 7.4%
The diagnostic laboratories segment is projected to register the fastest growth at a CAGR of 7.4% during the forecast period. Growth is supported by increasing demand for specialized testing, greater use of molecular and genetic diagnostics, and the expansion of automated high-throughput laboratory systems. Independent and reference laboratories can consolidate large testing volumes while offering specialized assays that may not be routinely performed within individual healthcare facilities.
Hospitals and other healthcare settings continue to generate substantial demand for clinical laboratory testing. Inpatient and outpatient facilities rely on laboratory results for diagnosis, treatment selection, disease monitoring, and follow-up care, while ongoing improvements in laboratory infrastructure and digital integration are helping streamline testing workflows.
Speak to an Analystto discuss market opportunities.
North America's clinical laboratory tests market accounted for 42.5% of the global market, reaching USD 61.91 billion in 2025, and is projected to grow at a CAGR of 6.4% during the forecast period. Market growth is driven by the high prevalence of chronic and infectious diseases, increasing demand for preventive and diagnostic testing, advanced laboratory infrastructure, growing adoption of molecular and genetic testing, and rising healthcare expenditure.
The United States represents the largest market in North America. Advanced healthcare infrastructure, high testing volumes, increasing prevalence of chronic diseases, growing demand for early diagnosis, and widespread adoption of advanced laboratory technologies continue to support market growth.
Canada's established healthcare system, increasing demand for diagnostic testing, rising chronic disease burden, and continued investment in laboratory infrastructure and advanced diagnostic technologies support steady market development.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe's clinical laboratory tests market accounted for 27.8% of the global market, reaching USD 40.49 billion in 2025, and is expected to register a CAGR of 5.9% during the forecast period. Growing demand for preventive healthcare, an aging population, increasing prevalence of chronic conditions, expanding diagnostic capabilities, and adoption of advanced laboratory testing technologies continue to support regional market growth.
Germany represents a major European market. Its established healthcare infrastructure, strong diagnostic laboratory network, aging population, and increasing demand for accurate and early disease detection continue to support clinical laboratory testing.
The United Kingdom's emphasis on early diagnosis, preventive healthcare, increasing demand for laboratory-based diagnostics, and continued modernization of healthcare services continue to strengthen market development.
The Asia Pacific clinical laboratory tests market accounted for 21.6% of the global market, reaching USD 31.46 billion in 2025, and is projected to grow at a CAGR of 8.3% during the forecast period. The region records the fastest growth among the listed markets, supported by expanding healthcare infrastructure, rising healthcare expenditure, increasing disease burden, growing awareness of early diagnosis, and rapid adoption of advanced diagnostic technologies.
China represents a major market within the Asia Pacific. Expanding healthcare infrastructure, increasing demand for disease screening, growing prevalence of chronic conditions, and investments in advanced diagnostic and laboratory technologies continue to drive market expansion.
India's expanding healthcare infrastructure, increasing diagnostic awareness, rising demand for preventive testing, growing burden of chronic and infectious diseases, and increasing availability of advanced laboratory services continue to strengthen market development.
Japan's aging population, sophisticated healthcare infrastructure, high demand for preventive and diagnostic testing, and increasing use of advanced laboratory technologies continue to support clinical laboratory test market growth.
Latin America's clinical laboratory tests market accounted for 4.9% of the global market, reaching USD 7.14 billion in 2025, and is expected to grow at a CAGR of 6.7% during the forecast period. Increasing healthcare expenditure, expanding diagnostic infrastructure, growing awareness of disease screening, and rising prevalence of chronic conditions continue to support regional market development.
Brazil represents a major regional market. Its large healthcare system, increasing demand for diagnostic services, growing chronic disease burden, and expanding laboratory infrastructure continue to create opportunities for clinical laboratory testing.
Mexico's expanding healthcare infrastructure, increasing diagnostic testing demand, growing emphasis on early disease detection, and rising prevalence of chronic diseases continue to support market growth.
The Middle East & Africa clinical laboratory tests market accounted for 3.2% of the global market, reaching USD 4.66 billion in 2025, and is anticipated to grow at a CAGR of 6.1% during the forecast period. Growing healthcare investments, expanding diagnostic infrastructure, increasing disease screening, and rising demand for advanced laboratory services continue to support regional market expansion.
The UAE's advanced healthcare infrastructure, growing investments in diagnostic services, increasing adoption of advanced laboratory technologies, and rising emphasis on preventive healthcare continue to support market development.
Saudi Arabia's healthcare infrastructure expansion, increasing investments in diagnostic services, growing focus on early disease detection, and rising demand for advanced clinical laboratory testing continue to strengthen market growth.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Ambulance Services Market Size, Share, Growth, Analysis, 2034
North America Clinical Trial Imaging Market Size, Share, and Forecast 2034
Europe Clinical Trial Imaging Market Analysis, Trends, Forecast Up to 2034
Asia Pacific Clinical Trial Imaging Market Size, Share and Forecast to 2034
India Pharmaceutical Stability and Storage Services Market Size, Share & Trends | Industry Report, 2034
Healthcare Regulatory Affairs Outsourcing Market Size, Share, 2034
We are featured on:
sales@straitsresearch.com